Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

Study Identifier
MAF/AGN/Facial/011
CT.gov Identifier
NCT01271452
EudraCT Identifier
2010-021401-20
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
    • Study Drug
  • botulinum toxin type A
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Moderate to severe glabellar frown lines
    Exclusion Criteria:
    * Diagnosis of myasthenia gravis or Eaton Lambert syndrome * Aesthetic treatment with botulinum toxin within 6 months or planned treatment with botulinum toxin for any reason during the study * Prior filler treatments, surgeries, insertion procedures in/to the glabellar region * Facial cosmetic procedures in the glabellar area within 6 months * Bleeding disorders or use of anticoagulants within 10 days * History of facial nerve palsy

    Protocol Summary

    This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.

    Study Locations

    Location
    Status
    Location
    Munich, Bavaria, Germany
    Status
    Not applicable